Biozona Weekly: Student research at UA; Commerce Authority appointments; Alzheimer’s drug development

July 28, 2011

By hammersmith


Want to receive Biozona Weekly in your email? You can sign up here.

DV grad awarded scholarship to continue cancer research
07/26/2011 | Ahwatukee Foothills News | Travis Roemhild

Andrew Ma is getting some real-world experience in doing undergraduate cancer research at the University of Arizona. Ma, who graduated from Desert Vista High School in 2009, was named a Beckman Scholar earlier this year, an award which pays for him to do research this summer, during the upcoming school year and the following summer. In total, becoming a scholar grants him up to $19,300 for paid research.

Arizona Commerce Authority board appointments named
07/26/2011 | Arizona Republic | Betty Beard

Gov. Jan. Brewer on Monday announced her 17 appointments to the new Arizona Commerce Authority’s board of directors. The public-private authority officially launched July 1 to replace the now-defunct Arizona Department of Commerce in an attempt to recruit more companies, investments and jobs to the state.

High school students get hands-on with scientific research
07/22/2011 | Inside Tucson Business | Patrick McNamara

The University of Arizona’s Bio5 Institute honored a group of high school students who participated in a summer internship program designed to help cultivate a new generation of scientists. High school students from across the state submitted applications to the KEYS (Keep Engaging Youth in Science) internship program in January. A total of 24 students were selected based on the applications, academic achievement and research interest.

Alzheimer’s disease genes aid the search for preventive drugs
07/22/2011 | Nature | David Cyranoski

Why do so many candidate drugs for Alzheimer’s disease fail in clinical trials? The question hung over this week’s annual Alzheimer’s Association International Conference in Paris. Researchers–including a group at the Banner Alzheimer’s Institute in Phoenix–are now rushing to study carriers of rare genetic forms of Alzheimer’s disease in search of an answer — and of a therapy that could save not only people affected by these ‘familial’ forms of the disease, but also victims of the more common ‘sporadic’ form that affects millions worldwide.